A research note from GlobalData suggests that AstraZeneca (LSE: AZN), the British pharma major responsible for the coronavirus vaccine Vaxzevria and antibody therapy Evusheld (tixagevimab), can expect positive uptake for the latter in Japan.
The long-acting antibody combination has been approved by Japan’s Ministry of Health, Labor and Welfare (MHLW) for the prevention and treatment of COVID-19.
The market could prove important to generating momentum in the near-term, with global sales of Evusheld having dropped in the second quarter, coming it at $445 million, down from $469 million at the start of the year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze